PURPOSE: A pharmaceutical composition containing piperazine dithioctate and glimepiride is provided to treat or prevent type 2 diabetes and to improve blood glucose. CONSTITUTION: A pharmaceutical composition for preventing or treating type 2 diabetes contains 10-80 wt% of piperazine dithioctate and 0.05-5 wt% of glimepiride. The thiotic acid of piperazine dithioctate is R-(+)-thiotic acid or S-(-)-thioctic acid. The weight ratio of the piperazine dithioctate and glimepiride is 10:1-1000:1.

Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2-methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-24- dione (rosiglitazone) or a pharmaceutically acceptable salt thereof and a sub-maximal amount of glimepiride. The composition is intended for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in mammals. The invention also relates to the use of the aforementioned pharmaceutical composition.

In the present invention there is described a pharmaceutical composition containing 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione that means the compound of the general formula (I) or a pharmaceutically acceptable derivative thereof submaximal amount of composition for support of insulin secretion being selected from the group consisting of glibenclamide glipizide gliclazide and glimepiride and a pharmaceutically acceptable carrier. There is also described ...

PROBLEM TO BE SOLVED: To provide a compound which modulates the activity of mammalian GPI-PLC (glycosylphosphatidylinositol-specific phospholipase C). SOLUTION: There are provided the compounds of formula (I) (wherein R1 R2 R3and R4are each independently H OH or F; and R5is 1-20C alkyl or 1-20C alkenyl) in all their stereoisomeric forms and mixtures thereof in all ratios and their physiologically acceptable salts. COPYRIGHT: (C)2011JPO&INPIT